Literature DB >> 31398626

Transgenic mice expressing human IL-32 develop adipokine profiles resembling those of obesity-induced metabolic changes.

Michelle S M A Damen1, Dov Ballak2, Zackary Sapinsley3, Xiyuan Bai4, Edward D Chan4, Douglas R Seals3, Calin D Popa5, Leo A B Joosten6.   

Abstract

Low-grade inflammation is associated with the development of insulin resistance in obese individuals. The present study aims to provide additional evidence strengthening the role of interleukin (IL)-32 in this key process. Using an IL-32 transgenic (IL-32tg) mouse model, we observed that IL-32tg fed a normal diet had greater body weight, due to greater accumulation of white adipose tissue (WAT) along with larger sized adipocytes. This led to metabolic consequences, with significant higher leptin levels and a trend towards hyperinsulinemia, indicating a phenotype resembling the metabolic syndrome. Adipocytes of IL-32tg mice were more prone to induce a pro-inflammatory response locally, which would be expected when predisposed to insulin resistance and type2 diabetes mellitus (T2D). In conclusion, our study provides novel evidence of a direct contribution of IL-32 to pathophysiological perturbations within the adipose tissue, possibly contributing to the metabolic syndrome that precedes frank insulin resistance and T2D. Future research should focus on the role of IL-32 in the obesity epidemic.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Insulin; Interleukin-32(IL-32); Metabolic changes; Obesity; Type II diabetes; White adipose tissue (WAT)

Mesh:

Substances:

Year:  2019        PMID: 31398626     DOI: 10.1016/j.cyto.2019.154793

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  1 in total

1.  Differential gene expression in nasal airway epithelium from overweight or obese youth with asthma.

Authors:  Zhongli Xu; Erick Forno; Edna Acosta-Pérez; Yueh-Ying Han; Franziska Rosser; Michelle L Manni; Glorisa Canino; Wei Chen; Juan C Celedón
Journal:  Pediatr Allergy Immunol       Date:  2022-04       Impact factor: 5.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.